Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds

American Cancer Society Announces New Pediatric Adolescent and Young Adult Cancer Journal

Colorectal Cancer Duloxetine Not Effective in Preventing Oxaliplatin-Induced Peripheral Neuropathy

Advanced Prostate Cancer Radiographic Progression and PSA Increase in Patients Treated With Enzalutamide

CLL Linked to Increased Skin Cancer Risk and Mortality